PRECISION BIOSCIENCES INC (DTIL)

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

Get insights into the top gainers and losers of Friday's pre-market session.

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

7 Biotech Stocks to Buy for Their Game-Changing Potential

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Precision BioSciences to Participate in Upcoming June Investor Conferences

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024

DTIL stock results show that Precision BioSciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precision BioSciences (NASDAQ:DTIL) just reported results for the first quarter...

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Precision BioSciences to Report First Quarter Results on May 13, 2024

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency